Robeco Institutional Asset Management’s Argan AGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.81M Hold
7,278
0.01% 509
2026
Q1
$3.96M Hold
7,278
0.01% 576
2025
Q4
$2.28M Sell
7,278
-327
-4% -$104K ﹤0.01% 656
2025
Q3
$2.05M Buy
7,605
+305
+4% +$69.9K ﹤0.01% 677
2025
Q2
$1.61M Buy
+7,300
New +$1.32M ﹤0.01% 705
2022
Q3
Sell
-6,133
Closed -$229K 936
2022
Q2
$229K Sell
6,133
-10,301
-63% -$394K ﹤0.01% 819
2022
Q1
$667K Buy
16,434
+2,340
+17% +$91.7K ﹤0.01% 742
2021
Q4
$545K Sell
14,094
-46
-0.3% -$1.92K ﹤0.01% 761
2021
Q3
$617K Sell
14,140
-614
-4% -$27.8K ﹤0.01% 756
2021
Q2
$706K Buy
14,754
+9,011
+157% +$449K ﹤0.01% 771
2021
Q1
$306K Buy
+5,743
New +$277K ﹤0.01% 832
2018
Q2
Sell
-79,931
Closed -$3.43M 960
2018
Q1
$3.43M Hold
79,931
0.02% 577
2017
Q4
$3.6M Buy
79,931
+24,213
+43% +$1.44M 0.02% 547
2017
Q3
$3.75M Sell
55,718
-1,353
-2% -$84.9K 0.02% 481
2017
Q2
$3.42M Hold
57,071
0.02% 494
2017
Q1
$3.78M Buy
+57,071
New +$3.99M 0.03% 480

Other funds holding AGX

Robeco Institutional Asset Management's AGX Position: Q2 2026 in Review

Robeco Institutional Asset Management held its Argan (AGX) position steady in Q2 2026 at 7,278 shares worth $5.81M. The position accounts for 0.01% of the portfolio, ranked #509.

Robeco Institutional Asset Management first reported a position in AGX in Q1 2017 and has held it in 16 quarters since. 562 funds tracked by Wall St. Rank hold AGX as of Q2 2026.

  • Robeco Institutional Asset Management held 7,278 shares of Argan worth $5.81M as of Q2 2026.
  • Robeco Institutional Asset Management left its Argan share count unchanged in Q2 2026.
  • Argan made up 0.01% of Robeco Institutional Asset Management's portfolio in Q2 2026, its #509 holding.
  • Robeco Institutional Asset Management first reported a position in Argan in Q1 2017 and has held it in 16 quarters since.
  • 562 funds tracked by Wall St. Rank held Argan as of Q2 2026.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.